First Step to In Vitro Diagnostic Regulation (IVDR) Certification for ZeptoMetrix®
ZeptoMetrix® has successfully completed its first EU Quality Management System Audit from British Standards Institution BSI, NB 2797, one of the notified bodies under the new In Vitro Diagnostics Regulation (IVDR).
BUFFALO, N.Y., Sept. 22, 2022 /PRNewswire-PRWeb/ -- ZeptoMetrix®, an Antylia Scientific company, is proud to announce it has successfully completed its first EU Quality Management System Audit from British Standards Institution BSI, NB 2797, one of the notified bodies under the new In Vitro Diagnostics Regulation (IVDR). The certification applies to the portfolio of ZeptoMetrix NATtrol™ control products that are the industry's preferred standard for molecular diagnostics testing and are supplied ready-to-use as independent third-party quality control materials.
"The IVDR is mandatory for any manufacturer of in vitro diagnostic devices (IVDs) to issue declarations of conformity, CE mark their products and to get them recertified in compliance with the new regulation," said Glenn Harrall, Vice President of Quality and Regulatory, Antylia Scientific.
"ZeptoMetrix is on-track to the full and timely transition from the In Vitro Diagnostics Directive (IVDD) to the IVDR," added Evangeline Gonzalez, Vice President/General Manager, ZeptoMetrix. "Our customers can be assured of continued availability of our CE-IVD marked portfolio along with our commitment to ongoing new product innovations."
Requirements of the IVDR regulation came into force on May 26, 2022. ZeptoMetrix CE-marked devices lawfully placed on the market in accordance with IVDD (directive 98/79/EC) prior to the date of application by virtue of a valid certificate may continue to be made available on the market until May 26, 2027.
For more information on ZeptoMetrix and NATtrol products, visit http://www.zeptometrix.com.
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Karen Danko, Antylia Scientific, 8473568556, email@example.com
Upcoming Life Sciences Events
- September 2023
- Barcelona: BioSpain 2023
- October 2023
- New York City: BioFuture
Latest company news
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China